Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) EBIT (2016 - 2020)

Forte Biosciences (FBRX) has disclosed EBIT for 5 consecutive years, with -$4.5 million as the latest value for Q4 2020.

  • On a quarterly basis, EBIT fell 109.61% to -$4.5 million in Q4 2020 year-over-year; TTM through Dec 2020 was -$46.3 million, a 204.6% decrease, with the full-year FY2024 number at -$36.6 million, down 12.67% from a year prior.
  • EBIT was -$4.5 million for Q4 2020 at Forte Biosciences, up from -$5.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $46.7 million in Q4 2019 to a low of -$34.8 million in Q2 2020.
  • A 5-year average of -$5.7 million and a median of -$8.5 million in 2016 define the central range for EBIT.
  • Peak YoY movement for EBIT: soared 344.64% in 2019, then tumbled 632.16% in 2020.
  • Forte Biosciences' EBIT stood at -$8.0 million in 2016, then tumbled by 34.04% to -$10.7 million in 2017, then tumbled by 78.8% to -$19.1 million in 2018, then surged by 344.64% to $46.7 million in 2019, then tumbled by 109.61% to -$4.5 million in 2020.
  • Per Business Quant, the three most recent readings for FBRX's EBIT are -$4.5 million (Q4 2020), -$5.0 million (Q3 2020), and -$34.8 million (Q2 2020).